<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atrophoderma of Pasini and Pierini</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atrophoderma of Pasini and Pierini</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atrophoderma of Pasini and Pierini</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elena Pope, MD, MSc, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald Laxer, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2706429858"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrophoderma of Pasini and Pierini (APP) is a rare skin disorder affecting dermal collagen and presenting with dermal atrophy. The classic clinical manifestations of APP are hyperpigmented or hypopigmented, depressed areas of skin on the trunk or extremities (<a class="graphic graphic_picture graphicRef109162" href="/d/graphic/109162.html" rel="external">picture 1</a>). It is unclear whether some cases of APP result from <em>Borrelia burgdorferi</em> infection. It is also uncertain whether APP is a distinct disease entity or a disorder on the spectrum of morphea (localized scleroderma).</p><p>The clinical manifestations, diagnosis, and treatment of APP will be reviewed here. Morphea is reviewed separately. (See  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a> and  <a class="medical medical_review" href="/d/html/16150.html" rel="external">"Morphea (localized scleroderma) in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/6399.html" rel="external">"Juvenile localized scleroderma"</a>.)</p><p class="headingAnchor" id="H346677078"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>APP was described in 1923 by Pasini as "atrofodermia idiopathica progressiva" [<a href="#rid1">1</a>] and later by Pierini as a disorder affecting primarily females and consisting of single or multiple depressed patches with sharp, well-defined borders [<a href="#rid2">2</a>]. In 1958, Canizares coined the term "idiopathic atrophoderma of Pasini and Pierini," crediting both Italian doctors [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H706225601"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>APP is rare. The exact incidence and prevalence are unknown. Most cases have been reported in White persons, particularly in European countries. Whether this relates to a higher prevalence of <em>Borrelia</em> infection in Europe or speaks more to more frequent clinical recognition of this entity in individuals with lightly pigmented skin is not clear. (See <a class="local">'Pathogenesis'</a> below.)</p><p>APP tends to present in the second or third decade of life [<a href="#rid3">3,4</a>]. However, pediatric onset of the disease has been reported, including congenital presentations [<a href="#rid5">5-8</a>]. APP is seen more frequently in females than in males [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H514580013"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of APP is poorly understood. An immunologic mechanism has been proposed based upon unusual staining of epidermal Langerhans cells and an abnormal T cell immunophenotype in the dermis [<a href="#rid10">10,11</a>]. The trigger for this immune reaction is unknown. <em>B. burgdorferi</em> infection has been proposed as a trigger based upon reports of APP occurring in the context of this infection. In a retrospective study of 34 patients with APP, 10 of 26 patients (38 percent) who were tested for antibodies against <em>B. burgdorferi</em> had elevated immunoglobulin G titers to <em>B. burgdorferi</em> compared with 14 percent of 43 healthy controls [<a href="#rid9">9</a>]. In addition, improvement in APP has occurred during treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> in a patient with immunoglobulin M antibodies to <em>B. burgdorferi </em>[<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2513795589"><span class="h1">RELATIONSHIP WITH MORPHEA</span><span class="headingEndMark"> — </span>The relationship between APP and morphea is controversial. Some authors propose that APP is a condition on the spectrum of morphea, representing the end result of the inflammatory process [<a href="#rid13">13,14</a>]. Arguments in support of this theory include reports describing the coexistence of the classic inflammatory and indurated plaques of morphea with APP, the progression of morphea plaques to APP, and clinical and pathologic similarities between APP and end-stage morphea [<a href="#rid9">9,10,13,14</a>]. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p>Evidence against the classification of APP as a manifestation of morphea includes an earlier average age of onset for pediatric morphea and longer disease course for APP than for morphea (an average active disease course of one to two decades versus five years); the subsequent development of induration in some cases of APP, which contradicts the theory that APP represents the end result of the inflammatory process in morphea; and pathologic differences [<a href="#rid3">3,10,11,15</a>]. Pathologically, APP may show decreased or clumped elastic fibers; in contrast, morphea may display inflammation and alteration of the appendageal structures [<a href="#rid3">3,10,11</a>]. (See  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H209305901"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical phenotype of APP consists of single or multiple well-demarcated, depressed areas of skin with dyspigmentation and an ovoid shape (<a class="graphic graphic_picture graphicRef109162" href="/d/graphic/109162.html" rel="external">picture 1</a>). Individual depressed areas are generally a few millimeters to several centimeters in diameter and may coalesce to form larger depressions. The most common type of dyspigmentation is brown discoloration; however, primarily hypopigmented APP has also been reported [<a href="#rid12">12,15</a>]. Individual lesions tend to be symmetrical in nature.</p><p>The border between normal and affected skin is striking, creating a "cliff-drop" appearance [<a href="#rid4">4</a>]. This presentation has gained additional descriptors, such as "footprints in the snow" and "Swiss cheese."</p><p>Although APP may present anywhere on the body, the more common areas are the trunk (particularly the lumbosacral area) and/or extremities. The face is rarely affected. An unusual presentation consisting of widespread small lesions, "generalized lenticular APP," has been reported [<a href="#rid16">16</a>]. The involved areas of skin in APP are asymptomatic and functional impairment is not expected.</p><p class="headingAnchor" id="H3070603257"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histologic changes, particularly in the early stages, may be minimal or nondiagnostic. The epidermis is normal. Dermal features consist of the flattening of the dermal papillae and rete pegs and a sparse perivascular and/or perifollicular lymphocytic infiltrate [<a href="#rid9">9,17</a>]. The collagen fibers may display clumping. The elastic fibers changes are variable, ranging from normal findings to fragmentation, and are best visualized with orcein stains [<a href="#rid9">9</a>].</p><p>The subtle and variable histologic findings in APP were demonstrated in a retrospective study that found no abnormalities on hematoxylin and eosin staining in 12 of 17 specimens of APP [<a href="#rid15">15</a>]. The remaining five specimens showed a sparse superficial perivascular or perifollicular lymphocytic infiltrate. Elastic stains revealed a moderate to severe decrease in elastic fibers with fragmentation in six specimens.</p><p class="headingAnchor" id="H1226023618"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of APP is made based upon the patient history and clinical findings. A biopsy is not necessary in most cases but may be employed to support the diagnosis in difficult cases. Laboratory investigations are not helpful for confirming the diagnosis but can identify patients with coexisting <em>B. burgdorferi</em> infection. Ultrasound examination with a 13 MHz probe may be capable of quantifying the degree of dermal atrophy in APP but is not necessary or routinely used in clinical practice [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1852530475"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The progressive development of asymptomatic, depressed, ovoid areas of skin with sharply demarcated borders on the trunk or extremities strongly suggests APP when a history of inflammation or induration at affected sites is absent. Limitation of these features to a Blaschkoid distribution suggests the alternative diagnosis of linear atrophoderma of Moulin (<a class="graphic graphic_figure graphicRef57219" href="/d/graphic/57219.html" rel="external">figure 1</a>).</p><p>A history of preceding skin inflammation and induration is suggestive of classic morphea. All patients should receive a full skin examination to evaluate for clinical manifestations of morphea. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/6399.html" rel="external">"Juvenile localized scleroderma", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H484184"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>The diagnosis of APP is primarily a clinical diagnosis. A skin biopsy may be used, particularly if morphea is in the differential diagnosis; however, the histologic changes may be subtle or nondiagnostic, particularly in early disease. (See <a class="local">'Histopathology'</a> above.)</p><p>The preferred type of biopsy in adults is a wedge (elliptical) biopsy or a 6 to 8 mm punch biopsy. In children, a smaller 4 mm punch biopsy may be preferable in order to limit scarring. Regardless of the type of biopsy performed, the specimen should include both affected and adjacent normal skin, and the specimen should be sectioned to include both portions. This facilitates the detection of subtle abnormalities within affected skin. (See  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques"</a>.)</p><p class="headingAnchor" id="H2772504169"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>There are no serologic markers that confirm a diagnosis of APP. Serologic evidence of inflammation is absent. Unlike morphea, there is no association with autoantibodies. (See  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults", section on 'Serum autoantibodies'</a>.)</p><p>The relationship between <em>B. burgdorferi</em> infection and APP remains uncertain; therefore, the value of serologic testing for <em>B. burgdorferi</em> infection is unclear. It is our preference to obtain serologic testing in patients with recent-onset APP in areas where Lyme disease is endemic because of the potential benefit of antibiotic therapy. (See <a class="local">'Treatment'</a> below and  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease"</a>.)</p><p class="headingAnchor" id="H3615920581"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of APP includes disorders characterized by cutaneous or subcutaneous atrophy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-stage morphea </strong>– The clinical course of morphea consists of an early inflammatory stage characterized by erythematous patches or plaques followed by sclerosis manifesting as firm, bound-down plaques and eventual progression (after months to years) to atrophic hypopigmented or hyperpigmented plaques (<a class="graphic graphic_picture graphicRef73769 graphicRef53822 graphicRef63984" href="/d/graphic/73769.html" rel="external">picture 2A-C</a>). The atrophic stage of morphea may exhibit epidermal atrophy (shiny, thin epidermis), dermal atrophy (poorly demarcated skin depressions with visible veins), and/or subcutaneous atrophy (poorly demarcated, deep loss of tissue). In contrast, APP exhibits well-circumscribed atrophy with a cliff drop-like border. The preceding history of inflammatory and sclerotic stages also helps to distinguish morphea from APP. (See  <a class="medical medical_review" href="/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/6399.html" rel="external">"Juvenile localized scleroderma", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrophoderma of Moulin </strong>– Atrophoderma of Moulin is a rare disorder that begins in childhood or adolescence. The disorder usually occurs on the trunk or extremities and presents with a unilateral band of hyperpigmented and atrophic plaques that follow the lines of Blaschko [<a href="#rid19">19</a>]. Inflammation is absent. The Blaschkoid distribution differentiates atrophoderma of Moulin from APP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders associated with subcutaneous atrophy </strong>– Dermal atrophy can be difficult to differentiate clinically from subcutaneous atrophy. Clinical signs that suggest subcutaneous atrophy rather than dermal atrophy secondary to APP include deep depressions, poorly demarcated borders, and a lack of pigmentary changes. Examples of causes of subcutaneous atrophy include local corticosteroid or insulin injections and chemical, physical, or inflammatory panniculitides (<a class="graphic graphic_picture graphicRef83791" href="/d/graphic/83791.html" rel="external">picture 3</a>). The patient history is useful for identifying corticosteroid or insulin-related atrophy. A biopsy can be useful for diagnosing panniculitides. (See  <a class="medical medical_review" href="/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a> and  <a class="medical medical_review" href="/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis"</a>.)</p><p></p><p>In addition, hyperpigmentation in APP should be distinguished from other causes of patchy cutaneous hyperpigmentation, such as lichen planus pigmentosus, erythema dyschromicum perstans (ashy dermatosis), and phytophotodermatitis. The presence of underlying skin depressions distinguishes APP.</p><p class="headingAnchor" id="H2951966610"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Although APP is a benign, asymptomatic, and non-life-threatening disorder, patients may seek treatment because of the disfiguring effects of APP. Treatment with topical corticosteroids, topical calcineurin inhibitors, oral antibiotics [<a href="#rid9">9,12</a>], or <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid20">20</a>] has been suggested based upon clinical experience; however, randomized trials are lacking and no treatment has been proven effective for improving the clinical manifestations or halting progression of the disease.</p><p>Cosmetic camouflage makeup can be used to decrease the appearance of APP [<a href="#rid21">21</a>]. A case report suggests that treatment of the associated hyperpigmentation with a Q-switched alexandrite laser may also improve the appearance of APP [<a href="#rid22">22</a>].</p><p>Treatment with an oral antibiotic regimen effective against <em>B. burgdorferi</em> infection is appropriate for patients with positive serology for <em>B. burgdorferi</em> infection. However, the efficacy of such a regimen is uncertain. In a retrospective study of 34 patients with APP (of which 10 of 26 patients tested for antibodies against <em>B. burgdorferi</em> with indirect immunofluorescence tested positive), 20 of 25 patients treated with oral penicillin (2 million units per day for two to three weeks), oral <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> (500 mg three times per day for two weeks), or both antibiotics showed clinical improvement and did not develop new active lesions during follow-up periods ranging from three months to eight years [<a href="#rid9">9</a>]. However, four of the six patients who did not receive antibiotic therapy and were available for follow-up also had no evident progression of disease. A separate case report describes improvement in the depth of APP lesions in a woman with positive serum immunoglobulin M antibodies to <em>B. burgdorferi</em> during treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg per day for three weeks) [<a href="#rid12">12</a>].</p><p>There are insufficient data to determine the best approach to antibiotic treatment. Patients with recent onset of APP may be the best candidates for treatment. Standard early Lyme disease treatment protocols can be used. (See  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease", section on 'Early localized disease (single erythema migrans)'</a>.)</p><p>General principles of the management of <em>B. burgdorferi</em> infection are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease"</a>.)</p><p class="headingAnchor" id="H1948890200"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term outcome of APP is usually good. It is likely that spontaneous improvement occurs over decades in many cases.</p><p class="headingAnchor" id="H4146591718"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Given the potential overlap between APP and morphea, long-term periodic follow-up of patients with APP to assess for signs of morphea (ie, skin inflammation, induration, and thickening) is prudent. Follow-up visits are also useful for monitoring disease progression and addressing patient (or parent/caregiver) questions and concerns, particularly for patients with recent-onset APP and pediatric APP. We suggest performing a skin examination at least once yearly.</p><p class="headingAnchor" id="H1146784344"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Atrophoderma of Pasini and Pierini (APP) is a rare cutaneous disorder characterized by dermal atrophy. APP can occur at any age but most often begins in the second or third decade of life. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The pathogenesis of APP is unclear. An immunologic mechanism has been proposed. <em>Borrelia burgdorferi</em> infection may also be a contributor. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relationship with morphea </strong>– The relationship between APP and morphea is controversial. Some authors consider APP a distinct disease entity, whereas others consider it a condition on the spectrum of morphea. (See <a class="local">'Relationship with morphea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The classic clinical findings of APP are ovoid, depressed areas of skin with sharply demarcated "cliff-drop" borders (<a class="graphic graphic_picture graphicRef109162" href="/d/graphic/109162.html" rel="external">picture 1</a>). Dyspigmentation, particularly hyperpigmentation, is usually present. Inflammation and skin induration are absent. The trunk and extremities are the most common sites of involvement. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A diagnosis of APP usually can be made based upon the patient history and skin examination. A biopsy may be helpful for supporting the diagnosis in difficult cases. Testing for <em>B. burgdorferi</em> infection is indicated in Lyme disease endemic areas. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– APP is a benign disorder; however, APP can be disfiguring. No treatment has been proven effective for APP. For patients found to have positive serology for <em>B. burgdorferi</em> infection, we suggest antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis and follow-up </strong>– Spontaneous improvement in APP may occur over decades. Given the potential relationship between APP and morphea, patients with APP should be examined periodically for clinical signs of morphea. (See <a class="local">'Prognosis'</a> above and <a class="local">'Follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pasini A. Atrofodermia idiopatica progressiva. G Ital Dermatol 1923; 58:75.</a></li><li><a class="nounderline abstract_t">Pierini L, Vivoli D. Atrofodermia progressiva (Pasini). G Ital Dermatol 1923; 77:403.</a></li><li><a class="nounderline abstract_t">CANIZARES O, SACHS PM, JAIMOVICH L, TORRES VM. Idiopathic atrophoderma of Pasini and Pierini. AMA Arch Derm 1958; 77:42.</a></li><li><a class="nounderline abstract_t">Pullara TJ, Lober CW, Fenske NA. Idiopathic atrophoderma of Pasini and Pierini. Int J Dermatol 1984; 23:643.</a></li><li><a class="nounderline abstract_t">Kang CY, Lam J. Congenital idiopathic atrophoderma of Pasini and Pierini. Int J Dermatol 2015; 54:e44.</a></li><li><a class="nounderline abstract_t">Kim SK, Rhee SH, Kim YC, et al. Congenital atrophoderma of Pasini and Pierini. J Korean Med Sci 2006; 21:169.</a></li><li><a class="nounderline abstract_t">Handler MZ, Alshaiji JM, Shiman MI, et al. Congenital idiopathic atrophoderma of Pasini and Pierini. Dermatol Online J 2012; 18:4.</a></li><li><a class="nounderline abstract_t">Bassi A, Remaschi G, Difonzo EM, et al. Idiopathic congenital atrophoderma of Pasini and Pierini. Arch Dis Child 2015; 100:1184.</a></li><li><a class="nounderline abstract_t">Buechner SA, Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol 1994; 30:441.</a></li><li><a class="nounderline abstract_t">Berman A, Berman GD, Winkelmann RK. Atrophoderma (Pasini-Pierini). Findings on direct immunofluorescent, monoclonal antibody, and ultrastructural studies. Int J Dermatol 1988; 27:487.</a></li><li><a class="nounderline abstract_t">Kernohan NM, Stankler L, Sewell HF. Atrophoderma of Pasini and Pierini. An immunopathologic case study. Am J Clin Pathol 1992; 97:63.</a></li><li><a class="nounderline abstract_t">Lee Y, Oh Y, Ahn SY, et al. A Case of Atrophoderma of Pasini and Pierini Associated with Borrelia burgdorferi Infection Successfully Treated with Oral Doxycycline. Ann Dermatol 2011; 23:352.</a></li><li><a class="nounderline abstract_t">Jablonska S, Blaszczyk M. Is superficial morphea synonymous with atrophoderma Pasini-Pierini? J Am Acad Dermatol 2004; 50:979.</a></li><li><a class="nounderline abstract_t">Kencka D, Blaszczyk M, Jabłońska S. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Dermatology 1995; 190:203.</a></li><li><a class="nounderline abstract_t">Saleh Z, Abbas O, Dahdah MJ, et al. Atrophoderma of Pasini and Pierini: a clinical and histopathological study. J Cutan Pathol 2008; 35:1108.</a></li><li><a class="nounderline abstract_t">Avancini J, Valente NY, Romiti R. Generalized lenticular atrophoderma of Pasini and Pierini. Pediatr Dermatol 2015; 32:389.</a></li><li><a class="nounderline abstract_t">Miteva L, Kadurina M. Unilateral idiopathic atrophoderma of Pasini and Pierini. Int J Dermatol 2006; 45:1391.</a></li><li><a class="nounderline abstract_t">Abe I, Ochiai T, Kawamura A, et al. Progressive idiopathic atrophoderma of Pasini and Pierini: the evaluation of cutaneous atrophy by 13-MHz B-mode ultrasound scanning method. Clin Exp Dermatol 2006; 31:462.</a></li><li><a class="nounderline abstract_t">Tan SK, Tay YK. Linear atrophoderma of Moulin. JAAD Case Rep 2016; 2:10.</a></li><li><a class="nounderline abstract_t">Carter JD, Valeriano J, Vasey FB. Hydroxychloroquine as a treatment for atrophoderma of Pasini and Pierini. Int J Dermatol 2006; 45:1255.</a></li><li><a class="nounderline abstract_t">Salsberg JM, Weinstein M, Shear N, et al. Impact of Cosmetic Camouflage on the Quality of Life of Children With Skin Disease and Their Families. J Cutan Med Surg 2016; 20:211.</a></li><li><a class="nounderline abstract_t">Arpey CJ, Patel DS, Stone MS, et al. Treatment of atrophoderma of Pasini and Pierini-associated hyperpigmentation with the Q-switched alexandrite laser: a clinical, histologic, and ultrastructural appraisal. Lasers Surg Med 2000; 27:206.</a></li></ol></div><div id="topicVersionRevision">Topic 108709 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atrofodermia idiopatica progressiva</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Atrofodermia progressiva (Pasini)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13486933" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Idiopathic atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6396245" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Idiopathic atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311149" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital idiopathic atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479086" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Congenital atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22559019" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Congenital idiopathic atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26374755" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Idiopathic congenital atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113457" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3065258" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Atrophoderma (Pasini-Pierini). Findings on direct immunofluorescent, monoclonal antibody, and ultrastructural studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728865" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Atrophoderma of Pasini and Pierini. An immunopathologic case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909207" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Case of Atrophoderma of Pasini and Pierini Associated with Borrelia burgdorferi Infection Successfully Treated with Oral Doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153911" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Is superficial morphea synonymous with atrophoderma Pasini-Pierini?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599381" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616761" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Atrophoderma of Pasini and Pierini: a clinical and histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234089" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Generalized lenticular atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076744" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Unilateral idiopathic atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681608" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Progressive idiopathic atrophoderma of Pasini and Pierini: the evaluation of cutaneous atrophy by 13-MHz B-mode ultrasound scanning method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27051814" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Linear atrophoderma of Moulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040461" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hydroxychloroquine as a treatment for atrophoderma of Pasini and Pierini.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26162859" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of Cosmetic Camouflage on the Quality of Life of Children With Skin Disease and Their Families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013382" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of atrophoderma of Pasini and Pierini-associated hyperpigmentation with the Q-switched alexandrite laser: a clinical, histologic, and ultrastructural appraisal.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
